Skip to main content

Table 2 Risk of bias assessment

From: Albumin versus crystalloid solutions in patients with the acute respiratory distress syndrome: a systematic review and meta-analysis

Trial Sequence generation Allocation concealment Blinding of participants, personnel and outcome assessors Incomplete outcome data Selective outcome reporting Other bias Overall risk of bias
Martin [29] Low Low Low Low Unclear High* High*
Martin [28] Low Low Low Low Unclear Low Unclear
SAFE [30] Unclear Low Low Low Unclear Low Unclear
  1. Sequence generation: Martin [28, 29] via computer generated list (four-subject-block randomization), SAFE [30]: unclear risk of bias because of minimization strategy; allocation concealment: all trials no evidence for inadequate concealment of allocation prior to assignment; blinding: all trials had double blind design with camouflage of study drugs and infusion systems and blinding of assessors and patients; incomplete outcome data: all trials low risk for attrition bias for mortality and oxygenation; selective outcome reporting: all trials: unclear risk of bias due to no statement regarding this item in text or supplement; other bias: Martin [29]: *high risk of bias due to concomitant furosemide treatment, in resulting violations of study protocol due to furosemide side effects, but albumin therapy was continued. Martin [28] and SAFE trial: no evidence of other sources of bias.